Changho Yu joined SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd., the mother company of SK Life Science, Inc., in 2002, and is currently the VP, Chief Strategy Officer. With a 20-year tenure at SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd., Mr. Yu has become an integral leader who brings a wealth of knowledge and experience to the strategy and investment team.

Through his prior experiences, Mr. Yu has successfully developed business strategies for the drug development business, helping to grow the business. He has excelled in analyzing industry environments, ranging from business development to competitor growth, and developing financial strategies based on his findings. He has also led the initial public offering of SK Biopharmaceuticals Co., Ltd. In 2020.

Before joining SK Life Science, Inc. and SK Biopharmaceuticals, Mr. Yu worked as an investment analyst for I&G Venture Capital Co., Ltd. Mr. Yu earned his bachelor’s degree from the Pohang University of Science and Technology, complemented by a master’s degree in biochemical engineering from the Pohang University of Science and Technology and by a master’s degree in management engineering from the Korea Advanced Institute of Science and Technology, Collage of Business. In addition, Mr. Yu is a CFA charterholder.